rchase Price") . If the Holder elects to convert this Note into Series A-I Preferred Stock, the Company shall take all corporate action to authorize the Series A-1 Preferred Stock with the rights, preferences and privileges set forth on Exhibit B attached hereto, as such rights, preferences and privileges may be modified prio

R PRIVATE PLACEMENT OF SERIES A-1 PREFERRED STOCK OF ANGIOCRINE BIOSCIENCE, INC. April 27, 2017 This memorandum summarizes the principal terms of the Series A-1 Preferred Stock financing of Angiocrine Bioscience, Inc. (the "Company"). The completion of the transactions contemplated by this memorandum will be subject to, am